NBIX Stock Forecast 2025-2026
Distance to NBIX Price Targets
NBIX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Neurocrine (NBIX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NBIX and similar high-potential opportunities.
Latest NBIX Stock Price Targets & Analyst Predictions
Based on our analysis of 33 Wall Street analysts, NBIX has a bullish consensus with a median price target of $161.50 (ranging from $96.00 to $192.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $101.38, the median forecast implies a 59.3% upside. This outlook is supported by 21 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Evan Seigerman at BMO Capital, suggesting a 5.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NBIX Analyst Ratings
NBIX Price Target Range
Latest NBIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NBIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2025 | Needham | Ami Fadia | Buy | Upgrade | $138.00 |
| Apr 14, 2025 | RBC Capital | Brian Abrahams | Outperform | Upgrade | $137.00 |
| Apr 4, 2025 | UBS | Ashwani Verma | Buy | Maintains | $137.00 |
| Mar 26, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $184.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Assumes | $150.00 |
| Feb 24, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $185.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $185.00 |
| Feb 10, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $163.00 |
| Feb 10, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $185.00 |
| Feb 7, 2025 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Feb 7, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $148.00 |
| Feb 7, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $147.00 |
| Feb 7, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $179.00 |
| Feb 7, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $163.00 |
| Feb 7, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $185.00 |
| Feb 4, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $185.00 |
| Jan 30, 2025 | UBS | Ashwani Verma | Buy | Maintains | $176.00 |
| Jan 8, 2025 | UBS | Ashwani Verma | Buy | Maintains | $162.00 |
| Dec 23, 2024 | Barclays | Carter Gould | Overweight | Maintains | $165.00 |
| Dec 23, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $160.00 |
Neurocrine Biosciences Inc. (NBIX) Competitors
The following stocks are similar to Neurocrine based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neurocrine Biosciences Inc. (NBIX) Financial Data
Neurocrine Biosciences Inc. has a market capitalization of $10.03B with a P/E ratio of 30.8x. The company generates $2.36B in trailing twelve-month revenue with a 14.5% profit margin.
Revenue growth is +21.8% quarter-over-quarter, while maintaining an operating margin of +20.9% and return on equity of +14.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Neurocrine Biosciences Inc. (NBIX) Business Model
About Neurocrine Biosciences Inc.
Develops treatments for neurological and endocrine disorders.
Neurocrine Biosciences operates by discovering, developing, and commercializing innovative therapies aimed at addressing unmet medical needs in neurological and endocrine-related disorders. The company generates revenue primarily through the sales of its approved products, such as Ingrezza for tardive dyskinesia and Orilissa for endometriosis pain, as well as through strategic partnerships like that with AbbVie.
Founded in 1992 and headquartered in San Diego, California, Neurocrine has established a strong market presence supported by a robust pipeline targeting diseases such as Parkinson’s and congenital adrenal hyperplasia. The company is committed to advancing healthcare solutions and improving patient outcomes through cutting-edge research and development.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,800
CEO
Mr. Kyle W. Gano Ph.D.
Country
United States
IPO Year
1996
Website
www.neurocrine.comNeurocrine Biosciences Inc. (NBIX) Latest News & Analysis
Neurocrine Biosciences' stock is around $100, up 850% since its 1996 IPO. Despite recent earnings misses, its pipeline, including Crenessity and Ingrezza, shows strong growth potential.
Neurocrine's strong historical growth and potential from its drug pipeline, despite recent setbacks, suggest it could be undervalued, presenting a potential buying opportunity for investors.
Neurocrine Biosciences appointed Dr. Sanjay Keswani as Chief Medical Officer, effective June 2, 2025. He brings over 20 years of leadership and R&D experience.
The appointment of Dr. Sanjay Keswani as CMO could enhance Neurocrine's R&D capabilities, potentially leading to new treatments and improved stock performance.
Neurocrine Biosciences reported that all patients treated with INGREZZA® achieved a therapeutic dose from Day One, unlike about half of those on Deutetrabenazine in a recent study.
The efficacy of INGREZZA® in achieving therapeutic doses immediately enhances its competitive position in the market, potentially boosting Neurocrine Biosciences' sales and stock value.
Neurocrine Biosciences (NBIX) is highlighted in a Motley Fool Scoreboard episode, offering insights into market trends and potential investment opportunities for investors.
Insights on Neurocrine Biosciences can highlight market trends and growth potential, influencing investment decisions and stock valuation in the biotech sector.
Neurocrine Biosciences (Nasdaq: NBIX) reported that most patients in the KINECT® 4 study achieved remission of tardive dyskinesia with INGREZZA® treatment, as presented at the 2025 Psychiatry Update Conference.
Positive data on INGREZZA's efficacy could boost Neurocrine Biosciences' stock, indicating strong market potential in treating tardive dyskinesia, which may attract investors seeking growth opportunities.
Neurocrine Biosciences presented KINECT®-HD study data at a symposium, showing significant improvements in Huntington's disease chorea with INGREZZA (valbenazine).
Positive data on INGREZZA's effectiveness in treating Huntington's disease could enhance Neurocrine Biosciences' market position, potentially driving stock value and investor interest.
Frequently Asked Questions About NBIX Stock
What is Neurocrine Biosciences Inc.'s (NBIX) stock forecast for 2025?
Based on our analysis of 33 Wall Street analysts, Neurocrine Biosciences Inc. (NBIX) has a median price target of $161.50. The highest price target is $192.00 and the lowest is $96.00.
Is NBIX stock a good investment in 2025?
According to current analyst ratings, NBIX has 21 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $101.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NBIX stock?
Wall Street analysts predict NBIX stock could reach $161.50 in the next 12 months. This represents a 59.3% increase from the current price of $101.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neurocrine Biosciences Inc.'s business model?
Neurocrine Biosciences operates by discovering, developing, and commercializing innovative therapies aimed at addressing unmet medical needs in neurological and endocrine-related disorders. The company generates revenue primarily through the sales of its approved products, such as Ingrezza for tardive dyskinesia and Orilissa for endometriosis pain, as well as through strategic partnerships like that with AbbVie.
What is the highest forecasted price for NBIX Neurocrine Biosciences Inc.?
The highest price target for NBIX is $192.00 from at , which represents a 89.4% increase from the current price of $101.38.
What is the lowest forecasted price for NBIX Neurocrine Biosciences Inc.?
The lowest price target for NBIX is $96.00 from Evan Seigerman at BMO Capital, which represents a -5.3% decrease from the current price of $101.38.
What is the overall NBIX consensus from analysts for Neurocrine Biosciences Inc.?
The overall analyst consensus for NBIX is bullish. Out of 33 Wall Street analysts, 21 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $161.50.
How accurate are NBIX stock price projections?
Stock price projections, including those for Neurocrine Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.